Serum EZH2 protein levels are decreased in people with multiple sclerosis: A pilot study

Abstract

BackgroundIn the immunopathology of multiple sclerosis (MS), genetic factors are thought to trigger autoimmunity by acting through T and B lymphocytes and microglia. The EZH2 gene is known to play a role in the development and differentiation of these cells. The aim of this study was to compare the protein levels of EZH2 in the blood samples of people with MS (PwMS) with the clinical characteristics of the patients and the control group. MethodsSociodemographic and clinical data and venous blood samples were obtained from PwMS and an age- and gender-matched control group. Samples were stored under appropriate conditions, and protein levels of EZH2 was measured by ELISA. ResultsThe study included 22 PwMS aged 20–54 years and 21 controls aged 21–51 years. EZH2 protein levels were lower in patients than in controls(p < 0.001). There was no difference between relapsing-remitting and progressive MS(p = 0.747). There was no difference between patients with a history of relapses in the past 2 years and those without relapses(p = 0.794). There was no difference between the patients with a normal neurological examination and those without (p = 0.478). There was no correlation between EZH2 protein levels and disease duration, time of first attack, age at diagnosis, treatment duration, Expanded Disability Status Scale. ConclusionIn our study, we found that EZH2 protein levels were lower in PwMS compared to the control group which suggests that decrease in EZH2 protein expression may play a role in the immunopathogenesis of MS. This study may provide preliminary information for future research.